Good EULAR Response In Patients With Early Rheumatoid Arthritis
NCT ID: NCT01558089
Last Updated: 2016-11-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
76 participants
OBSERVATIONAL
2013-03-31
2015-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
etanercept + methotrexate
etanercept
according to SmPC and clinical practice
methotrexate
according to SmPC and clinical practice
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
etanercept
according to SmPC and clinical practice
methotrexate
according to SmPC and clinical practice
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. 18 years of age and older at the time of consent
3. Patients with moderate-to-severe active rheumatoid arthritis, who satisfy the 2010 Rheumatoid Arthritis Classification Criteria
4. Patients who have been prescribed for first time to receive treatment with MTX + Etanercept prior to enrollment to this study, following routine clinical practice and according to the approved SmPC,
5. Patients with DAS28 ≥ 3.2
6. Duration of disease symptoms ≥ 6 weeks and ≤2 years
7. Failure to respond to prior DMARDs including MTX monotherapy according to routine clinical practice.
Exclusion Criteria
2. History of or present anti-TNFa or other biologic therapy for the treatment of RA
3. Known significant concurrent medical disease according to investigator's opinion and the current SmPC
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
G. Gennimatas General Hospital /Rheumatology Clinic
Athens, Attica, Greece
Ippokrateio General Hospital of Athens / 2nd internal Medicine Clinic of the University of Athens
Athens, Attica, Greece
University General Hospital of Heraklion
Heraklion, Creete, Greece
G. Papanikolaoy
Thessaloniki, Exochi, Greece
424 Military Hospital
Thessaloniki, Thessalonikis, Greece
Euromedica Kyanous Stavros
Thessaloniki, Thessaloniki, Greece
Laiko General Peripheral Hospital
Athens, , Greece
Peripheral University General Hospital of Larissa
Larissa, , Greece
"Olympion therapeutic center" General Clinic of Patras
Pátrai, , Greece
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B1801138
Identifier Type: -
Identifier Source: org_study_id